Cimzia-starter

Drug Details

Certolizumab, marketed under the brand name Cimzia, is an injectable medication primarily used to manage several autoimmune conditions including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn's disease. It is also effective for non-radiographic axial spondyloarthritis. This drug is administered every 2 to 4 weeks and can be used alone or in combination with other treatments like methotrexate. Certolizumab works as a tumor necrosis factor (TNF) blocker. TNF is a protein in the body that contributes to inflammation. By inhibiting TNF, certolizumab reduces inflammation, thereby alleviating the symptoms associated with these autoimmune diseases. While taking this medication, some individuals may experience side effects such as upper respiratory infections, urinary tract infections, and skin rashes. It is essential to consult with your healthcare provider before starting this medication to ensure it is suitable for your condition and to discuss any potential interactions with other treatments you may be receiving.